Obagi Condition & Enhance Clear(Hydroquinone USP, 4%)Skin Bleaching Cream Obagi Condition & Enhance Blender (Hydroquinone USP, 4%)Skin Bleaching Cream | CONDITION AND ENHANCE CLEAR [OMP, INC.] | BioPortfolio

12:21 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Rx Only


Hydroquinone is 1,4-benzenediol. Hydroquinone occurs as fine, white needles. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C H O; molecular weight is 110.0.

Obagi Condition & Enhance Blender contains Hydroquinone USP 40 mg/gm in a base of purified water, glycerin, cetyl alcohol, PPG-2 myristyl ether propionate, sodium lauryl sulfate, TEA-salicylate, lactic acid, phenyl trimethicone, tocopheryl acetate, sodium metabisulfite, ascorbic acid, methylparaben, saponins, disodium EDTA, BHT, and propylparaben.

Obagi Condition & Enhance Clear contains Hydroquinone USP 40 mg/gm in a base of purified water, cetyl alcohol, glycerin, sodium lauryl sulfate, stearyl alcohol, tocopheryl acetate, ascorbic acid, sodium metabisulfite, lactic acid, saponins, disodium EDTA, methylparaben, BHT, propylparaben, and butylparaben.

Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (dopa) and suppression of other melanocyte metabolic processes.

Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunblocking agents or sunscreen agents contained in Obagi Condition & Enhance.

The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

Prior history of sensitivity or allergic reaction to this product or any of its ingredients. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.

Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check in 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. Close patient supervision is recommended.

Avoid contact with eyes. In case of accidental contact, patient should rinse eyes thoroughly with water and contact physician. A bitter taste and anesthetic effect may occur if applied to lips.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Contains sodium metabisulfite, a sulfite that may cause serious allergic type reactions (e.g., hives, itching, wheezing, anaphylaxis, severe asthma attacks) in certain susceptible persons.


Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment.

Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Safety and effectiveness in children below the age of 12 years have not been established.

No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the medication should be discontinued and the physician notified immediately.

A thin application should be applied to the affected area twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent, a sun blocking agent, or protective clothing to cover bleached skin when using and after using this product in order to prevent repigmentation.

Obagi Condition and Enhance Blender is available as follows:

Obagi Condition and Enhance Clear is available as follows:

2 oz. (57 gm) bottle NDC 62032-115-36
1 oz. (28.5 gm) bottle NDC 62032-115-10
2 oz. (57 gm) bottle NDC 62032-117-36

Store at 25°C (77°F); excursion permitted to 15°C-30°C (59°F-86°F).


OMP, Inc.Long Beach, CA 90802USA1-800-636-7546

80707910U Rev. 6/07



NDC 62032-117-36 AM • PM3


Skin Bleaching & Corrector Cream Hydroquinone USP, 4% Rx Only

NET WT. 2 OZ. (57 g)



NDC 62032-115-36PM5


Skin Lightener & Blending Cream Hydroquinone USP, 4% Rx Only

NET WT. 2 OZ. (57 g)


Compugen Ltd.

Active Ingredients


Drugs and Medications [7 Associated Drugs and Medications listed on BioPortfolio]

Condition and enhance system [omp, inc.]

Obagi Condition & Enhance Clear (Hydroquinone USP, 4%) Skin Bleaching Cream  Obagi Condition & Enhance Blender (Hydroquinone USP, 4%) Skin Bleaching Cream

Condition and enhance system [omp, inc.]

Obagi Condition & Enhance Clear(Hydroquinone USP, 4%)Skin Bleaching Cream Obagi Condition & Enhance Blender (Hydroquinone USP, 4%)Skin Bleaching Cream

Condition and enhance system [omp, inc.]

Obagi Condition & Enhance Clear (Hydroquinone USP, 4%) Skin Bleaching Cream Obagi Condition & Enhance Blender (Hydroquinone USP, 4%) Skin Bleaching Cream

Acd-a [fenwal inc.]

ACD-A (032922700)

Prenate enhance [avion pharmaceuticals, llc]


Clinical Trials [3804 Associated Clinical Trials listed on BioPortfolio]

Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types

This is a multi-site, randomized, double-masked, contralateral, 2 treatment x 2 period crossover, dispensing, five-visit study to gain clinical insights of the study lenses and solutions.

Evaluation of Clear Aligner Trays to Straighten Teeth

The objective of this study is to evaluate the efficacy of Clear Aligners to correct tooth malocclusions with the use of attachments and/or buttons, as determined by the amount of teeth mo...

Hemodynamic Optimization During Single Kidney Transplantation With MostcareUP

There are currently no clear recommendations on hemodynamic targets during kidney transplantation and most anesthesiologists rely on empiric or obsolete parameters such as CVP. The ...

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

The trial will recruit up to 120 patients; 90 with ovarian clear cell carcinoma and up to 30 with endometrial clear cell carcinoma. Patients will be randomised between chemotherapy and Nin...

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Study MO39939 is an open-label, single-arm, multicenter trial in patients with unresectable, locally-advanced or metastatic, clear or non-clear cell renal cell carcinoma (RCC) who have not...

PubMed Articles [9010 Associated PubMed Articles listed on BioPortfolio]

A simple and novel method to enhance As (V) removal by zero valent iron and activated iron media through air injection at intervals.

A simple and novel method was developed at first time to enhance As (V) removal by zero valent iron (ZVI) and activated ZVI/FeO media (AIM) through air injection at intervals. Fe (II) was essential to...

Optimization of Casting in Early-onset Scoliosis.

Early-onset scoliosis is a spine deformity that presents before the age of 3 years. When compared with age-matched controls, children with the condition are known to be at risk for significant morbidi...

How understanding the temperaments can help clinicians to make a correct diagnosis of bipolar mood disorders: 10 case reports.

The temperament is a key factor when assessing a patient within the bipolar spectrum. The temperaments are conditions in their own right within the bipolar spectrum, since they are 'soft' forms of bip...

Compression therapy and exercise: enhancing outcomes.

Compression therapy is the main method used within the treatment and management of lymphoedema and chronic oedema. The increasing prevalence of the condition, which has multiple causes, such as geneti...

Response of the reactor performance and microbial community to a shift of ISDD process from micro-aerobic to anoxic condition.

Micro-aerobic condition has proven to be effective in enhancing sulfide oxidation to elemental sulfur (S) during integrated simultaneous desulfurization and denitrification process (ISDD). In this stu...

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record